CYRX
CryoPort Inc. · NASDAQ
- Market cap
- $1.01B
CryoPort Inc. (CYRX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for CYRX, including 2 earnings updates, 2 SEC filings and 2 insider trades. The most recent was published Nov 12, 2026.
CYRX rankings
Financial highlights
Full financials- Revenue, TTM
- $192.44M
- Revenue growth
- +11.8%
- Net income, TTM
- -$41.30M
- Net margin
- -21.5%
- Free cash flow, TTM
- -$18.81M
- Cash
- $279.18M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks23+400%
2026-05-242026-11-15
Mix690d
- Earnings2(33%)
- SEC Filings2(33%)
- Insider2(33%)
Activity · 52 weeks4829 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERChief Scientific Officer Sawicki Mark W sold $199,261 worth of shares (10,000 units at $19.93), decreasing direct ownership by 10% to 92,356 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERDirector Hancock Daniel M exercised 74,379 shares at a strike of $9.91 and sold $1,502,976 worth of shares (74,379 units at $20.21) (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECSEC Form 10-Q filed by CryoPort Inc.10-Q - Cryoport, Inc. (0001124524) (Filer)
- SECCryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cryoport, Inc. (0001124524) (Filer)
- PRCryoport Reports Third Quarter 2026 Financial ResultsThird quarter revenue grew 14% year-over-year to $50.2 millionCommercial Cell and Gene Therapy revenue increased 20% year-over-yearSupporting a record 788 global clinical trials and 23 commercially approved cell and gene therapies as of September 30, 2026Raises full-year 2026 revenue guidance to $197 million - $199 millionNASHVILLE, Tenn., Nov. 5, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2026.
- PRCryoport to Report Third Quarter 2026 Financial Results on November 5, 2026NASHVILLE, Tenn., Oct. 22, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2026 on Thursday, November 5, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2026 in Review", providing a review of Cryoport's key operational developments, business milestones and strategic initiatives, will be issued at 4:05 p.m. ET on Thursday, No
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
- INSIDERPresident, CEO Shelton Jerrell sold $429,385 worth of shares (28,800 units at $14.91) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,201,814 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECSEC Form 10-Q filed by CryoPort Inc.10-Q - Cryoport, Inc. (0001124524) (Filer)
- SECCryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cryoport, Inc. (0001124524) (Filer)
- PRCryoport Reports Second Quarter 2026 Financial ResultsSecond quarter revenue grew 8% year-over-year to $49.0 millionLife Sciences Services revenue increased 15% year-over-yearBioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026. Jerrell Shelton, CEO of Cryoport, co
- PRCryoport to Report Second Quarter 2026 Financial Results on August 6, 2026NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Second Quarter 2026 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Thursday, August 6, 2026.
- PRCryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy ProgramsIntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B
- SECSEC Form S-8 filed by CryoPort Inc.S-8 - Cryoport, Inc. (0001124524) (Filer)
- SECSEC Form 15-12G filed by CryoPort Inc.15-12G - Cryoport, Inc. (0001124524) (Filer)
- INSIDERChief Digital and Tech Officer Zecchini Edward J exercised 35,000 shares at a strike of $4.80 and sold $507,563 worth of shares (35,000 units at $14.50) (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECCryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Cryoport, Inc. (0001124524) (Filer)
- INSIDERDirector Baddour Linda was granted 10,350 shares, increasing direct ownership by 18% to 68,099 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERChief Financial Officer Stefanovich Robert sold $2,756,984 worth of shares (169,427 units at $16.27), decreasing direct ownership by 61% to 109,850 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERDirector Hancock Daniel M was granted 10,350 shares, increasing direct ownership by 18% to 69,052 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERDirector Hariri Robert J was granted 10,350 shares, increasing direct ownership by 20% to 61,625 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERDirector Mandalam Ramkumar was granted 10,350 shares and sold $358,452 worth of shares (23,214 units at $15.44), decreasing direct ownership by 16% to 67,894 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECSEC Form SD filed by CryoPort Inc.SD - Cryoport, Inc. (0001124524) (Filer)
- SECSEC Form 10-Q filed by CryoPort Inc.10-Q - Cryoport, Inc. (0001124524) (Filer)
- SECCryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cryoport, Inc. (0001124524) (Filer)
CYRX FAQ
10 questionsWhat does CryoPort Inc. do?
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are...What is the latest news on CYRX?
In the last 30 days Quantisnow tracked 6 wire items for CYRX: 2 earnings updates, 2 SEC filings and 2 insider trades. The most recent was published on November 12, 2026.What is CYRX revenue?
CryoPort Inc. (CYRX) reported $192.44M of revenue for the twelve months ended Sep 30, 2026. That is up 11.8% from the year before. Revenue for fiscal 2025 was $176.18M.Is CYRX profitable?
No. CryoPort Inc. reported a net loss of $41.30M for the twelve months ended Sep 30, 2026.How much cash and debt does CYRX have?
CryoPort Inc. reported $279.18M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does CYRX stock trade?
CryoPort Inc. (CYRX) is listed on NASDAQ.What sector and industry is CYRX in?
CryoPort Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CYRX?
Across the last 8 analyst actions on CryoPort Inc., there were 4 upgrades and 1 downgrade. The most recent action was from KeyBanc Capital Markets: Overweight on 2025-08-06. Recent price targets range from $8.00 to $16.00.What companies are similar to CYRX?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare CYRX side-by-side with any of them on Quantisnow.How can I track CYRX on Quantisnow?
Quantisnow aggregates CryoPort Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYRX to receive live email and push alerts on every new disclosure.